Medicaid Directors Urge Federal Policy Changes To Fight High-Cost Drugs
This article was originally published in The Pink Sheet Daily
The National Association of Medicaid Directors asks Congress to enact policies lessening the impact of Sovaldi and other high-cost specialty medications on state budgets. NAMD's options include direct price controls and higher mandatory rebates for certain drugs.
You may also be interested in...
Pharma has been almost wholly successful in shifting the ground in the US drug pricing debate away from high-cost “specialty” products and towards the large gap between list and net prices, with the most intense focus on older medicines like insulin. What happens when the debate shifts back?
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.